Catalog No.
Product Name
Application
Product Information
Citations
-
MAO Inhibitor
Benmoxin is a potent monoamine oxidase (MAO) inhibitor that plays a crucial role in the modulation of neurotransmitter levels. This compound is primarily utilized in depression research, offering insights into the biochemical pathways associated with mood disorders. Benmoxin serves as a valuable tool for studying the effects of MAO inhibition on neurochemical balance and potential therapeutic interventions. -
MAO-B Inhibitor
PSB-1491 is a selective and competitive inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.386 nM for human MAO-B. This compound exhibits over 25,000-fold selectivity towards MAO-B compared to MAO-A, making it a valuable tool for studying neurodegenerative diseases and exploring potential therapeutic applications in disorders such as Parkinson's disease. Its high potency and selectivity make PSB-1491 an important reagent for research focused on modulating monoamine neurotransmitter levels. -
hMAO-B Inhibitor
hMAO-B-IN-4 is a selective and reversible inhibitor of human monoamine oxidase-B (hMAO-B), demonstrating an IC50 of 0.067 µM and a Ki of 0.03 µM. It exhibits less potency against hMAO-A with an IC50 value of 33.82 µM. This compound effectively penetrates the blood-brain barrier, making it a valuable tool for research into neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. -
MAO-B Inhibitor
MAO-B-IN-33 is a potent, reversible, and selective inhibitor of monoamine oxidase-B (MAO-B) with an IC50 of 0.021 μM for MAO-B and 26.805 μM for MAO-A, highlighting its selectivity. Its distinctive action is attributed to steric hindrance caused by differences in amino acid residues between MAO-A and MAO-B. This compound effectively inhibits cerebral MAO-B activity and demonstrates the ability to mitigate MPTP-induced dopaminergic neuronal loss in murine models. MAO-B-IN-33 shows promise for applications in Parkinson's disease research. -
Monoamine Oxidase Inhibitor
(+)-Cinchonaminone acts as a monoamine oxidase inhibitor, demonstrating significant activity in the modulation of neurotransmitter levels. This compound is valuable for research applications focusing on neuropharmacology, depression, and other mood disorders, where the regulation of monoamines is critical. -
hMAO-B Inhibitor
hMAO-B-IN-2 is a potent and selective inhibitor of human monoamine oxidase B (hMAO-B), exhibiting a competitive reversible mechanism with an IC50 of 4 nM. This compound is characterized by its ability to penetrate the blood-brain barrier and demonstrates low toxicity alongside significant neuroprotective effects in SH-SY5Y neuroblastoma cells. hMAO-B-IN-2 is suitable for research applications related to Alzheimer's disease and also serves as a versatile click chemistry reagent, featuring an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. -
MAO-B Inhibitor
MAO-B-IN-16 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 1.55 µM. This compound is valuable for investigating the role of MAO-B in central nervous disorders, particularly in the context of Parkinson's disease. Its use can enhance understanding of disease mechanisms and contribute to the development of therapeutic strategies targeting MAO-B. -
MAO Inhibitor
Echitovenidine is a naturally occurring alkaloid isolated from Alstonia yunnanensis, functioning as a potent monoamine oxidase (MAO) inhibitor. This compound demonstrates significant biological activity in modulating neurotransmitter levels, making it valuable for research in neuropharmacology and the exploration of mood disorders. Echitovenidine's mechanism of action can facilitate studies aimed at understanding the role of MAO in various neurological conditions. -
MAO-B Inhibitor
1-Methyl-2-undecyl-4(1H)-quinolone is a selective and irreversible inhibitor of type B monoamine oxidase (MAO-B). It exhibits potent inhibition with IC50 and Ki values of 15.3 μM and 9.91 μM, respectively, without affecting type A monoamine oxidase (MAO-A) activity. This quinolone alkaloid, derived from the fresh leaves and fruits of Evodia rutaecarpa, is valuable in research focused on neurological disorders and the modulation of neurotransmitter levels. -
MAO A/B Inhibitor
MAO-IN-3 is a reversible and competitive inhibitor of monoamine oxidase A and B, exhibiting Ki values of 0.6 μM and 0.2 μM, respectively. This compound demonstrates significant anti-proliferative effects on LN-229 glioblastoma cells, with an IC50 of 0.8 μM. MAO-IN-3 is suitable for research applications focused on cancer biology and therapeutic development targeting monoamine oxidase pathways. -
MAO-B Inhibitor
MAO-B-IN-14 is a selective monoamine oxidase-B (MAO-B) inhibitor, exhibiting an IC50 of 0.95 μM and a Ki of 0.55 μM against human MAO-B. This compound demonstrates significant potential for research applications focused on neurodegenerative disorders, particularly those involving dopaminergic pathways. Its inhibitory properties make it a valuable tool for studies exploring the role of MAO-B in neurological conditions and therapeutic interventions targeting this enzyme. -
MAO-B Inhibitor
MAO-B-IN-47 is a selective inhibitor of monoamine oxidase B (MAO-B) with a Ki of 875 nM. This compound demonstrates neuroprotective effects in SH-SY5Y cells treated with 6-hydroxydopamine (6-OHDA), showing an IC50 greater than 100 μM. MAO-B-IN-47 is valuable for research into neurological disorders, particularly Parkinson's disease, by potentially mitigating neuronal damage associated with MAO-B activity. -
hMAO-B Inhibitor
hMAO-B-IN-6 is a potent and selective inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 67.02 nM. This compound has demonstrated significant efficacy in reversing Scopolamine-induced cognitive impairment in mouse models of Alzheimer's disease. Its application in research highlights its potential for further investigations into neurodegenerative disorders and cognitive enhancement therapies. -
MAO-B Inhibitor
MAO-B-IN-22 is a potent inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 0.014 μM. This compound exhibits strong antioxidant activity and effective metal chelation capabilities, contributing to its significant neuroprotective effects. It demonstrates suitable blood-brain barrier permeability, making it a valuable reagent for research applications focused on neurodegenerative diseases and oxidative stress. -
MAO-B Inhibitor
MAO-B ligand-1 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating IC50 values of 3.83 nM against human MAO-B and 22.57 nM against human MAO-A. This compound is valuable for studying the regulation of neurotransmitters and the biochemical pathways involved in neurodegenerative diseases. MAO-B ligand-1 is suitable for applications in pharmacological research and the development of therapeutic agents targeting MAO-B related disorders. -
MAO-B Inhibitor
MAO-B-IN-11 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 of 1.3 μM. This compound exhibits neuroprotective activity, making it a valuable tool for research focused on neurodegenerative diseases and related therapeutic strategies. Its potency and selectivity position MAO-B-IN-11 as an important reagent for studies on the modulation of neurotransmitter metabolism. -
MAO-A And 5-HT-uptake Inhibitor
Sercloremine hydrochloride is a selective and reversible inhibitor of monoamine oxidase A (MAO-A) and serotonin (5-HT) uptake. This compound is primarily utilized in research related to depression, offering insights into the modulation of serotonin levels and its effects on mood regulation. Its dual mechanism of action makes it valuable for exploring therapeutic approaches in depressive disorders. -
MAO-B Inhibitor
MAO-B-IN-5 is a selective and orally active inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 of 0.204 µM. This compound is designed for research applications related to neurodegenerative disorders, particularly Parkinson's disease (PD). Its potent inhibition of MAO-B may contribute to the understanding of dopamine metabolism and neuroprotection in PD studies. -
MAO Inhibitor
MAO-IN-5 is a selective monoamine oxidase (MAO) inhibitor, demonstrating significant potential for modulating neurotransmitter levels. This compound exhibits promising blood-brain barrier permeability and a high gastrointestinal absorption rate, making it valuable for in vivo studies. MAO-IN-5 is primarily utilized in research addressing neurological disorders, contributing to the understanding of MAO-related pathways in various pathologies. -
MAO-B Inhibitor
MAO-B-IN-51 is a selective, orally active inhibitor of monoamine oxidase B (MAO-B) with a blood-brain barrier permeability. It demonstrates an IC50 value of 48.9 nM, indicating potent inhibition of MAO-B activity. This compound has been shown to enhance long-term memory, making it a valuable tool for research on neurodegenerative disorders and cognitive function. -
MAO-A Inhibitor
2-PAT is a reversible inhibitor of monoamine oxidase A (MAO-A) with an IC50 value of 0.721 µM, demonstrating significant biochemical activity. Additionally, it acts as an inactivator of monoamine oxidase B (MAO-B) with an IC50 of 14.6 µM. This compound is valuable for research related to Parkinson’s disease and depression, providing a useful tool for investigating the therapeutic potential of MAO inhibitors in neurological disorders. -
MAO-B Inhibitor
C175-0062 is a selective monoamine oxidase B (MAO-B) inhibitor. This compound exhibits neuroprotective properties that are significant for understanding and researching neurodegenerative disorders such as Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). C175-0062 serves as a valuable tool in the study of pathways involved in these conditions, contributing to the development of therapeutic strategies. -
Type A MAO Inhibitor
Bazinaprine is an orally active type A monoamine oxidase (MAO) inhibitor. It exhibits significant potential in modulating neurotransmitter levels, making it a valuable tool in research related to depression. This compound may help elucidate the mechanisms underlying mood disorders and facilitate the development of novel therapeutic strategies. -
hMAO-B Inhibitor
MAO-B-IN-28 is a potent human monoamine oxidase B (hMAO-B) inhibitor with an IC50 of 1.9±0.5 nM. This compound demonstrates significant neuroprotective activity, making it a valuable tool in the study of neurodegenerative diseases. Its selective inhibition of hMAO-B may contribute to the understanding of oxidative stress and neuroinflammation in relevant research applications. -
MAO-B Inhibitor
MAO-B-IN-23 is a reversible and competitive inhibitor of monoamine oxidase B (MAO-B), with an IC50 value of 1.44 μM and a Ki of 0.51 μM. This compound is valuable for investigating the role of MAO-B in neurodegenerative diseases and can be used in studies focused on neuroprotective strategies and modulation of neurotransmitter levels. Its specific inhibition of MAO-B makes it a useful tool for research into Parkinson's disease and related disorders. -
MAOB Inhibitor
MAO-B-IN-40 is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 0.493 μM for human MAO-B. This compound exhibits significant neuroprotective and antioxidant properties, making it a valuable tool in the study of neurodegenerative disorders. MAO-B-IN-40 is particularly relevant in Parkinson's disease research, where the modulation of MAO-B activity may help mitigate disease progression and improve therapeutic outcomes. -
MAO-A Inhibitor
(R)-Pirlindole mesylate is a selective and reversible inhibitor of Monoamine oxidase A (MAO-A), exhibiting an IC50 of 0.43 μM against MAO-A with minimal effect on MAO-B. This compound demonstrates notable antidepressant activity, as evidenced by a significant reduction in immobility time in the forced swim test. Additionally, (R)-Pirlindole mesylate effectively inhibits Reserpine-induced palpebral ptosis in behavioral mice models. Its properties make it a valuable tool for research into depression and related disorders. -
MAO Inhibitor
MAO-IN-4 is a potent monoamine oxidase (MAO) inhibitor, exhibiting IC50 values of 0.07 μM for MAO-A and 0.75 μM for MAO-B. This compound is valuable for research focused on neurodegenerative disorders and mood disorders, particularly depression and Parkinson’s disease (PD). Its selective inhibition of MAO enzymes provides insight into therapeutic approaches for these conditions. -
MAO-B Inhibitor
Almoxatone is a potent, orally bioavailable inhibitor of monoamine oxidase B (MAO-B). Its primary mechanism involves the selective inhibition of MAO-B enzyme activity, which plays a crucial role in the metabolism of neurotransmitters such as dopamine. Almoxatone demonstrates significant potential in research applications related to neurodegenerative disorders and mood regulation, making it a valuable tool for studying the neurological implications of monoamine metabolism. -
MAO-B Inhibitor
1-Methyl-2-nonyl-4(1H)-quinolone is a selective inhibitor of monoamine oxidase B (MAO-B). This quinolone alkaloid demonstrates significant inhibitory activity on leukotriene biosynthesis, with an IC50 value of 12.1 μM. It is a valuable tool for research in neurodegenerative diseases and inflammation-related studies. -
Monoamine Oxidase Inhibitor
MAO-B-IN-34 is a selective monoamine oxidase B (MAO-B) inhibitor that plays a crucial role in regulating the breakdown of neurotransmitters such as dopamine. By inhibiting MAO-B, this compound may enhance dopaminergic signaling, making it a valuable tool in research related to neurodegenerative diseases like Parkinson's disease. Its application extends to studying the pharmacological effects of neurotransmitter modulation in various neurological contexts. -
MAO-B Inhibitor
MAO-B-IN-17 is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 value of 5.08 μM. This compound plays a significant role in modulating monoaminergic neurotransmission and is applicable in research focused on Parkinson's disease and related neurodegenerative disorders. Its specificity for MAO-B makes it a valuable tool for studying the implications of monoamine metabolism in neurological conditions. -
MAO-B Inhibitor
MAO-B-IN-52 is a potent inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 83.7 μM. This compound demonstrates significant antioxidant activity, making it a valuable tool for research into neurodegenerative conditions such as Alzheimer's disease. Its targeting of MAO-B may provide insights into potential therapeutic strategies for modulating neuroinflammatory processes and oxidative stress. -
MAO-A Inhibitor
Moclobemide N-Oxide is an N-oxide metabolite of Moclobemide that primarily acts as a monoamine oxidase A (MAO-A) inhibitor. This compound exhibits inhibitory activity towards MAO-A, albeit typically at lower concentrations. It can be quantified through UV absorption at 240 nm, making it a valuable tool for studying the mechanisms of MAO-A inhibition in chemical research and pharmacological applications. -
MAO-B Inhibitor
MAO-B-IN-6 is a potent and selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.019 µM. This compound demonstrates superior efficacy compared to Safinamide in both in vitro and in vivo assays. MAO-B-IN-6 holds promise for advancing research in the pathophysiology and treatment of Parkinson's disease (PD). -
MAO-B Inhibitor
Milacemide hydrochloride is an orally active inhibitor of monoamine oxidase B (MAO-B) and a glycinamide derivative with demonstrated anticonvulsant properties. This compound effectively modulates neurotransmitter levels by decreasing dihydroxyphenylacetic acid and homovanilic acid while enhancing dopamine and serotonin concentrations in the caudate nucleus. Milacemide hydrochloride shows potential for investigation in Alzheimer's disease research and related neurodegenerative disorders. -
MAO-B Inhibitor
MAO-B-IN-30 is a selective inhibitor of monoamine oxidase B (MAO-B) that effectively crosses the blood-brain barrier, with IC50 values of 19.176 µM for MAO-A and 0.082 µM for MAO-B. This compound exhibits significant antiproliferative activity while demonstrating non-cytotoxic effects. Additionally, MAO-B-IN-30 effectively reduces pro-inflammatory cytokines, including TNF-alpha and IL-6, as well as the NF-kB pathway. Its properties make it a valuable tool for research into the mechanisms underlying Parkinson's disease. -
MAO-B Inhibitor
Monoamine Oxidase B inhibitor 5 is a selective and reversible inhibitor of monoamine oxidase B (hMAO-B) with an IC50 of 67.3 nM and a Ki value of 82.5 nM. This compound demonstrates favorable pharmacokinetic properties and low toxicity in rat models. Additionally, Monoamine Oxidase B inhibitor 5 has shown efficacy in alleviating MPTP-induced motor impairment in Parkinson’s disease mouse models, with the capability to cross the blood-brain barrier. This makes it a valuable tool for research in neurodegenerative diseases and MAO-B related pathways. -
MAO-B Inhibitor
MAO-B-IN-19 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 0.67 μM. This compound demonstrates neuroprotective effects, making it a valuable tool for research in neurodegenerative diseases. Additionally, it possesses anti-inflammatory properties, supporting its application in studying inflammation-related pathways in various biological systems. -
MAO Inhibitor
Safrazine is an irreversible, non-specific monoamine oxidase (MAO) inhibitor that is orally active. It is primarily utilized in research focused on depression and related mood disorders by modulating monoamine levels in the brain. This compound can aid in studies aimed at understanding the biochemical pathways underlying depressive states and the effects of MAO inhibition. -
MAO-B Inhibitor
MAO-B-IN-27 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting a potent inhibitory effect with an IC50 value of 8.9 nM against human MAO-B. This compound is valuable for research applications related to neurodegenerative diseases, particularly Parkinson's disease (PD), facilitating investigations into its biochemical pathways and potential therapeutic approaches. -
MAO-B Inhibitor
MAO-B-IN-44 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 1.01 μM while showing minimal inhibition of MAO-A (IC50 = 14.4 μM). This compound effectively reduces the degradation of neurotransmitters, particularly dopamine, making it a valuable tool for studying neurodegenerative disorders linked to MAO-B dysregulation, such as Parkinson's disease. Its selective inhibition can aid in understanding the role of MAO-B in neural pathophysiology and contribute to the development of targeted therapies. -
MAO-B Inhibitor
MAO-B-IN-29 is a selective inhibitor of monoamine oxidase B (MAO-B), a key enzyme involved in the degradation of neurotransmitters such as dopamine. This compound exhibits significant biological activity by modulating MAO-B activity, which is relevant for research into neurological disorders, including Parkinson's disease and depression. MAO-B-IN-29 serves as an important tool for studying the role of MAO-B in neurotransmitter metabolism and potential therapeutic interventions. -
hMAO-B Inhibitor
hMAO-B-IN-5 is a potent and selective reversible inhibitor of human monoamine oxidase-B (hMAO-B), exhibiting an IC50 of 120 nM and a Ki of 33 nM. This compound is valuable for studying neurodegenerative diseases, as it modulates the metabolism of neuroactive amines and has implications in the treatment of conditions such as Parkinson's disease. Researchers can utilize hMAO-B-IN-5 to explore hMAO-B's role in neurobiology and drug development. -
MAO-B Inhibitor
MAO-B-IN-15 is a selective inhibitor of monoamine oxidase B (MAO-B), with an IC50 value of 13.5 μM, demonstrating its ability to effectively inhibit enzymatic activity through π-π interactions with the Tyr 326 residue. This compound is integral for research focused on neurodegenerative disorders, particularly Parkinson's disease, by potentially enhancing dopaminergic neurotransmission and reducing oxidative stress associated with neuronal degeneration. -
MAO Inhibitor
Pivalylbenzhydrazine is a potent inhibitor of monoamine oxidase (MAO), an enzyme involved in the oxidative deamination of neurotransmitters. This compound has been shown to decrease cartilage growth in normal rats, indicating its potential influence on cellular growth processes. Pivalylbenzhydrazine is useful for research applications related to depression and other neurological conditions by modulating neurotransmitter levels. -
MAO-B Inhibitor
Monoamine Oxidase B inhibitor 2 is a selective and reversible inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 of 1.33 nM. This compound exhibits antioxidant and anti-neuroinflammatory properties, making it valuable for research related to neurodegenerative disorders. Due to its ability to cross the blood-brain barrier, Monoamine Oxidase B inhibitor 2 is particularly useful in the study of Parkinson's disease mechanisms and potential therapeutic interventions. -
MAO-B Inhibitor
(E)-CHBO4 is a potent inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.023 μM. This compound is valuable for investigating the biochemical pathways involved in neurodegenerative disorders such as Parkinson's disease. Its selective inhibition of MAO-B makes it an important tool for studying the role of this enzyme in dopamine metabolism and potential therapeutic strategies. -
MAO Inhibitor
Mebanazine is a potent monoamine oxidase (MAO) inhibitor. It has shown promise in modulating monoamine levels, thus making it a valuable tool in the study of depressive disorders. Mebanazine's ability to enhance neurotransmitter availability supports research in neuropharmacology and the development of antidepressant therapies. -
Monoamine Oxidase Inhibitor
N-2-Cyclohexylethyl-N-methylamine is a monoamine oxidase inhibitor that effectively reduces the activity of the MAO enzyme. This compound is derived from A. ridigula Benth and plays a crucial role in neuromodulation. It can be utilized in research applications involving neurological disorders and the study of serotonin and dopamine metabolism.
